Your browser doesn't support javascript.
loading
Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study.
Braun, Molly R; Moore, Anne C; Lindbloom, Jonathan D; Hodgson, Katherine A; Dora, Emery G; Tucker, Sean N.
Affiliation
  • Braun MR; Vaxart Inc., 170 Harbor Way Suite 300, South San Francisco, CA 94080, USA.
  • Moore AC; Vaxart Inc., 170 Harbor Way Suite 300, South San Francisco, CA 94080, USA.
  • Lindbloom JD; School of Biochemistry and Cell Biology, University College Cork, T12 XF62 Cork, Ireland.
  • Hodgson KA; National Institute of Bioprocessing Research and Training, A94 X099 Dublin, Ireland.
  • Dora EG; Vaxart Inc., 170 Harbor Way Suite 300, South San Francisco, CA 94080, USA.
  • Tucker SN; Vaxart Inc., 170 Harbor Way Suite 300, South San Francisco, CA 94080, USA.
Vaccines (Basel) ; 12(9)2024 Aug 23.
Article de En | MEDLINE | ID: mdl-39339987
ABSTRACT
Therapeutic vaccination can harness the body's cellular immune system to target and destroy cancerous cells. Several treatment options are available to eliminate pre-cancerous and cancerous lesions caused by human papillomaviruses (HPV), but may not result in a long-term cure. Therapeutic vaccination may offer an effective, durable, and minimally intrusive alternative. We developed mucosally delivered, recombinant, non-replicating human adenovirus type 5 (rAd5)-vectored vaccines that encode HPV16's oncogenic proteins E6 and E7 alongside a molecular dsRNA adjuvant. The induction of antigen-specific T cells and the therapeutic efficacy of rAd5 were evaluated in a mouse model of HPV tumorigenesis where E6E7-transformed cells, TC-1, were implanted subcutaneously in C57BL/6 mice. After tumor growth, mice were treated intranasally with rAd5 vaccines expressing the wildtype form of E6E7 (rAd5-16/E6E7Wt) in combination with an anti-PD-1 antibody or isotype control. Animals treated with rAd5-16/E6E7Wt with and without anti-PD-1 had significant reductions in tumor volume and increased survival compared to controls. Further, animals treated with rAd5-16/E6E7Wt had increased CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) and produced a cytotoxic tumor microenvironment. In a second study, the immunogenicity of a non-transformative form of E6E7 (rAd5-16/E6E7Mu) and a vaccine encoding predicted T cell epitopes of E6E7 (rAd5-16/E6E7epi) were evaluated. These vaccines elicited significant reductions in TC-1 tumor volume and increased survival of animals. Antigen-specific CD8+ T effector memory cells were observed in the animals treated with E6E7-encoding rAd5, but not in the rAd5-empty group. The work described here demonstrates that this mucosal vaccination can be used therapeutically to elicit specific cellular immunity and further identifies a clinical candidate with great potential for the treatment and prevention of human cervical cancer.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Vaccines (Basel) Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Vaccines (Basel) Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Suisse